[Use of synthetic chromogenic substrates for the control of antithrombosis therapy with small doses of heparin].
D000368:Aged; D000990:Antithrombin III / Q000378:metabolism; D002863:Chromogenic Compounds; D004151:Dipeptides; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D006493:Heparin / Q000008:administration & dosage* / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000601:surgery; D009842:Oligopeptides; D011183:Postoperative Complications / Q000517:prevention & control*; D013918:Thrombin Time; D013927:Thrombosis / Q000517:prevention & control*
D002863:Chromogenic Compounds; D004151:Dipeptides; D005338:Fibrin Fibrinogen Degradation Products; D009842:Oligopeptides; C006871:calcium heparin; C015608:benzoyl-Ile-Glu-Gly-Arg-p-nitroanilide; C021129:S 2238; D000990:Antithrombin III; D006493:Heparin
Die Anwendung von synthetischen chromogenen Substraten zur Kontrolle der antithrombotischen Therapie mit kleinen Heparin-Dosen.